Efficacy and Safety of the Soricle for Subjective Tinnitus Relief

This was a prospective, single-center, randomized, double-blind, sham-controlled exploratory clinical trial designed to evaluate the efficacy and safety of Soricle, a Class III medical device combining transcutaneous vagus nerve stimulation (tVNS) and sound stimulation, for the treatment of subjective tinnitus.

Participants diagnosed with subjective tinnitus were randomly assigned in a 1:1 ratio to either the active treatment group or the sham control group. The investigational device was applied daily for 8 weeks.

The primary objective of the study was to evaluate the improvement in tinnitus symptoms, and secondary objectives included additional efficacy assessments and safety evaluations. Safety was monitored throughout the study, including the assessment of adverse events.

The study was conducted in accordance with ICH-GCP guidelines and was approved by the Institutional Review Board. All participants provided written informed consent prior to participation.

Inclusion criteria

• Adults aged 18 years or older
• Patients with subjective tinnitus
• Able to understand and provide informed consent
• Willing to comply with study procedures

Exclusion criteria

• Objective tinnitus
• Severe hearing loss requiring immediate treatment
• History of neurological or psychiatric disorders that may affect study outcomes
• Use of other tinnitus treatments during the study period
• Any condition that, in the investigator's judgment, may interfere with study participation